1. Pfizer-BioNTech’s three-dose vaccine for children 6 months to 4 years old prevented symptomatic disease in clinical trials, according to The Wall Street Journal.
In a study data review by the FDA, U.S. health regulators found the risk of adverse effects were comparable to older age groups, according to the Journal.
2. The FDA deemed Moderna’s vaccine “safe and effective” for 6-month-old to 5-year-old children, the Washington Post reported.
Moderna’s two-dose vaccine candidate promoted lower adverse reactions compared to children in other age groups, with the exception of fever, which affected 21 percent to 26 percent of children after either dose, according to the agency’s report.
The FDA will meet June 15 to discuss each vaccine’s results.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
